Exact Sciences Corporation Company Profile (NASDAQ:EXAS)

About Exact Sciences Corporation (NASDAQ:EXAS)

Exact Sciences Corporation logoExact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXAS
  • CUSIP: 30063P10
  • Web: www.exactsciences.com
Capitalization:
  • Market Cap: $4.44587 billion
  • Outstanding Shares: 111,192,000
Average Prices:
  • 50 Day Moving Avg: $35.97
  • 200 Day Moving Avg: $27.25
  • 52 Week Range: $13.05 - $42.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -42.18
  • P/E Growth: -1.25
Sales & Book Value:
  • Annual Revenue: $132.9 million
  • Price / Sales: 33.17
  • Book Value: $2.78 per share
  • Price / Book: 14.26
Profitability:
  • EBIDTA: ($144,340,000.00)
  • Net Margins: -83.08%
  • Return on Equity: -41.91%
  • Return on Assets: -37.34%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 10.23%
  • Quick Ratio: 9.97%
Misc:
  • Average Volume: 3.43 million shs.
  • Beta: 0.73
  • Short Ratio: 5.89
 
Frequently Asked Questions for Exact Sciences Corporation (NASDAQ:EXAS)

What is Exact Sciences Corporation's stock symbol?

Exact Sciences Corporation trades on the NASDAQ under the ticker symbol "EXAS."

How were Exact Sciences Corporation's earnings last quarter?

Exact Sciences Corporation (NASDAQ:EXAS) released its earnings results on Tuesday, July, 25th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.10. The company earned $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 41.91%. View Exact Sciences Corporation's Earnings History.

Where is Exact Sciences Corporation's stock going? Where will Exact Sciences Corporation's stock price be in 2017?

14 brokerages have issued 1 year price targets for Exact Sciences Corporation's shares. Their forecasts range from $15.00 to $50.00. On average, they anticipate Exact Sciences Corporation's share price to reach $38.93 in the next year. View Analyst Ratings for Exact Sciences Corporation.

What are analysts saying about Exact Sciences Corporation stock?

Here are some recent quotes from research analysts about Exact Sciences Corporation stock:

  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (6/27/2017)
  • 2. Cowen and Company analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)

Are investors shorting Exact Sciences Corporation?

Exact Sciences Corporation saw a decrease in short interest in June. As of June 15th, there was short interest totalling 22,030,168 shares, a decrease of 10.1% from the May 31st total of 24,493,802 shares. Based on an average daily trading volume, of 4,597,547 shares, the short-interest ratio is currently 4.8 days. Approximately 20.3% of the shares of the company are short sold.

Who are some of Exact Sciences Corporation's key competitors?

Who are Exact Sciences Corporation's key executives?

Exact Sciences Corporation's management team includes the folowing people:

  • Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer
  • Jeffrey Thomas Elliott, Chief Financial Officer
  • Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director
  • Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer
  • D. Scott Coward, Senior Vice President, General Counsel, Secretary
  • David A. Thompson, Lead Independent Director
  • Thomas D. Carey, Independent Director
  • James E. Doyle, Independent Director
  • John A. Fallon M.D., Independent Director
  • Daniel J. Levangie, Independent Director

Who owns Exact Sciences Corporation stock?

Exact Sciences Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Skylands Capital LLC (0.28%), US Bancorp DE (0.23%), Russell Investments Group Ltd. (0.16%), Handelsbanken Fonder AB (0.15%), American National Insurance Co. TX (0.15%) and Handelsinvest Investeringsforvaltning (0.05%). Company insiders that own Exact Sciences Corporation stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Maneesh Arora. View Institutional Ownership Trends for Exact Sciences Corporation.

Who sold Exact Sciences Corporation stock? Who is selling Exact Sciences Corporation stock?

Exact Sciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Skylands Capital LLC, Creative Planning, Janney Montgomery Scott LLC, Strs Ohio, US Bancorp DE, Affinity Investment Advisors LLC and Eqis Capital Management Inc.. Company insiders that have sold Exact Sciences Corporation stock in the last year include D Scott Coward, Graham Peter Lidgard, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for Exact Sciences Corporation.

Who bought Exact Sciences Corporation stock? Who is buying Exact Sciences Corporation stock?

Exact Sciences Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Handelsinvest Investeringsforvaltning, Russell Investments Group Ltd., Adams Diversified Equity Fund Inc., Sit Investment Associates Inc., Legato Capital Management LLC, Aperio Group LLC and Financial Architects Inc. Company insiders that have bought Exact Sciences Corporation stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy and Lionel Sterling. View Insider Buying and Selling for Exact Sciences Corporation.

How do I buy Exact Sciences Corporation stock?

Shares of Exact Sciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exact Sciences Corporation's stock price today?

One share of Exact Sciences Corporation stock can currently be purchased for approximately $39.65.


MarketBeat Community Rating for Exact Sciences Corporation (NASDAQ EXAS)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  690
MarketBeat's community ratings are surveys of what our community members think about Exact Sciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Exact Sciences Corporation (NASDAQ:EXAS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $38.93 (1.82% downside)

Analysts' Ratings History for Exact Sciences Corporation (NASDAQ:EXAS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Canaccord GenuityBoost Price TargetBuy -> Buy$42.00 -> $45.00HighView Rating Details
7/26/2017Bank of America CorporationReiterated RatingBuyHighView Rating Details
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 -> $46.00HighView Rating Details
7/26/2017Craig HallumReiterated RatingBuy$41.00 -> $46.00HighView Rating Details
7/26/2017Lake Street CapitalBoost Price TargetHold -> Hold$30.00 -> $41.00MediumView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$35.00 -> $45.00LowView Rating Details
7/7/2017Benchmark Co.Set Price TargetBuy$50.00LowView Rating Details
6/7/2017StephensSet Price TargetHold$28.00MediumView Rating Details
6/1/2017Robert W. BairdReiterated RatingOutperform$40.00LowView Rating Details
6/1/2017Jefferies Group LLCSet Price TargetBuy$35.00MediumView Rating Details
5/31/2017Cowen and CompanyReiterated RatingOutperform$45.00HighView Rating Details
5/1/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral$21.00 -> $33.00MediumView Rating Details
4/28/2017Leerink SwannSet Price TargetBuy$38.00MediumView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$29.00N/AView Rating Details
10/30/2015WedbushLower Price Target$7.00 -> $6.50N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Exact Sciences Corporation (NASDAQ:EXAS)
Earnings by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Earnings History by Quarter for Exact Sciences Corporation (NASDAQ EXAS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017Q2 2017($0.37)($0.27)$47.73 million$57.65 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exact Sciences Corporation (NASDAQ:EXAS)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.40)($0.42)
Q2 20174($0.41)($0.33)($0.38)
Q3 20175($0.38)($0.28)($0.33)
Q4 20175($0.36)($0.30)($0.33)
Q1 20182($0.33)($0.26)($0.30)
Q2 20182($0.33)($0.22)($0.28)
Q3 20182($0.32)($0.18)($0.25)
Q4 20182($0.31)($0.17)($0.24)
Q1 20191($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exact Sciences Corporation (NASDAQ:EXAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exact Sciences Corporation (NASDAQ:EXAS)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 85.07%
Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017D Scott CowardSVPSell1,987$35.21$69,962.27View SEC Filing  
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.82View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.28View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.08View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.35View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.00View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.72View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.70View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.75View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.00View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.50View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.00View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.34View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.92View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Exact Sciences Corporation (NASDAQ:EXAS)
Latest Headlines for Exact Sciences Corporation (NASDAQ:EXAS)
Source:
DateHeadline
seekingalpha.com logoExact Sciences Crushes Estimates Again - Seeking Alpha
seekingalpha.com - July 27 at 5:08 AM
finance.yahoo.com logoExact Sciences: Blowout!
finance.yahoo.com - July 27 at 12:04 AM
finance.yahoo.com logoEXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 26, 2017
finance.yahoo.com - July 27 at 12:04 AM
americanbankingnews.com logoExact Sciences Corporation (NASDAQ:EXAS) Receives "Buy" Rating from Craig Hallum
www.americanbankingnews.com - July 26 at 8:03 PM
americanbankingnews.com logoExact Sciences Corporation (NASDAQ:EXAS) PT Raised to $45.00
www.americanbankingnews.com - July 26 at 7:27 PM
seekingalpha.com logoEXACT Sciences' (EXAS) CEO Kevin Conroy on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 26 at 7:04 PM
finance.yahoo.com logoEdited Transcript of EXAS earnings conference call or presentation 25-Jul-17 9:00pm GMT
finance.yahoo.com - July 26 at 7:04 PM
finance.yahoo.com logoRisk-Reward Still Suggests Exact Sciences Is A Buy, But Be Cautious
finance.yahoo.com - July 26 at 7:04 PM
finance.yahoo.com logoPacira Pharmaceuticals Inc (PCRX) and EXACT Sciences Corporation (EXAS) Are Shaking Up the Market
finance.yahoo.com - July 26 at 7:04 PM
americanbankingnews.com logoExact Sciences Corporation (NASDAQ:EXAS) Receives Buy Rating from Bank of America Corporation
www.americanbankingnews.com - July 26 at 3:10 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Expected to Post Quarterly Sales of $52.62 Million
www.americanbankingnews.com - July 26 at 2:03 PM
americanbankingnews.com logoExact Sciences Corporation (NASDAQ:EXAS) Price Target Raised to $46.00
www.americanbankingnews.com - July 26 at 1:24 PM
fool.com logoWhy EXACT Sciences Corporation Is Rising Today
www.fool.com - July 26 at 1:14 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - July 26 at 12:30 PM
seekingalpha.com logoEXACT Sciences Corporation 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - July 26 at 4:46 AM
americanbankingnews.com logoExact Sciences Corporation (NASDAQ:EXAS) Upgraded to "Hold" by Vetr Inc.
www.americanbankingnews.com - July 26 at 12:45 AM
finance.yahoo.com logoExact Sciences Earnings OutLook: Not An Easy Task
finance.yahoo.com - July 25 at 6:45 PM
finance.yahoo.com logoInvestor Network: Exact Sciences Corporation to Host Earnings Call
finance.yahoo.com - July 25 at 6:45 PM
finance.yahoo.com logoCologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests
finance.yahoo.com - July 25 at 6:45 PM
finance.yahoo.com logoExact Sciences reports 2Q loss
finance.yahoo.com - July 25 at 6:44 PM
prnewswire.com logoExact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees - PR Newswire (press release)
www.prnewswire.com - July 21 at 8:20 PM
nasdaq.com logoWhy Exact Sciences (EXAS) Might Surprise This Earnings Season - Nasdaq
www.nasdaq.com - July 21 at 3:17 PM
finance.yahoo.com logoWhy Exact Sciences (EXAS) Might Surprise This Earnings Season
finance.yahoo.com - July 21 at 3:17 PM
americanbankingnews.com logoCanaccord Genuity Reiterates "Buy" Rating for Exact Sciences Corporation (NASDAQ:EXAS)
www.americanbankingnews.com - July 20 at 7:45 PM
benzinga.com logoWhat To Expect From Exact Sciences' Pending Q2 Release - Benzinga
www.benzinga.com - July 20 at 4:06 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 18 at 5:02 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 18 at 9:11 AM
nasdaq.com logoEXAS Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - July 13 at 12:16 AM
prnewswire.com logoExact Sciences to host second-quarter 2017 results, annual meeting webcasts ...
www.prnewswire.com - July 11 at 6:09 AM
finance.yahoo.com logoExact Sciences to host second-quarter 2017 results, annual meeting webcasts and calls
finance.yahoo.com - July 10 at 6:26 PM
americanbankingnews.com logoExact Sciences Corporation Expected to Earn Q3 2017 Earnings of ($0.35) Per Share (EXAS)
www.americanbankingnews.com - July 10 at 7:37 AM
finance.yahoo.com logoExact Sciences: Lifting Sales Estimates
finance.yahoo.com - July 8 at 10:41 AM
americanbankingnews.com logoBenchmark Co. Analysts Give Exact Sciences Corporation (NASDAQ:EXAS) a $50.00 Price Target
www.americanbankingnews.com - July 7 at 7:28 PM
americanbankingnews.com logoCraig Hallum Comments on Exact Sciences Corporation's Q3 2018 Earnings (NASDAQ:EXAS)
www.americanbankingnews.com - July 7 at 12:02 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Given New $41.00 Price Target at Craig Hallum
www.americanbankingnews.com - July 7 at 10:18 AM
americanbankingnews.com logoVetr Inc. Downgrades Exact Sciences Corporation (NASDAQ:EXAS) to Hold
www.americanbankingnews.com - July 7 at 12:38 AM
americanbankingnews.com logoExact Sciences Corporation (NASDAQ:EXAS) SVP D Scott Coward Sells 1,987 Shares
www.americanbankingnews.com - July 5 at 7:45 PM
prnewswire.com logoTechnical Snapshots for These Medical Laboratories Stocks -- Exact Sciences ...
www.prnewswire.com - June 30 at 6:46 PM
americanbankingnews.com logo Analysts Expect Exact Sciences Corporation (EXAS) Will Post Quarterly Sales of $47.71 Million
www.americanbankingnews.com - June 30 at 3:36 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Sees Significant Decline in Short Interest
www.americanbankingnews.com - June 29 at 7:13 AM
americanbankingnews.com logoVetr Inc. Downgrades Exact Sciences Corporation (EXAS) to Hold
www.americanbankingnews.com - June 29 at 12:16 AM
nasdaq.com logoWhy Exact Sciences (EXAS) Could Beat Earnings Estimates Again - Nasdaq
www.nasdaq.com - June 28 at 11:10 PM
finance.yahoo.com logoWhy Exact Sciences (EXAS) Could Beat Earnings Estimates Again
finance.yahoo.com - June 28 at 6:10 PM
americanbankingnews.com logo-$0.37 Earnings Per Share Expected for Exact Sciences Corporation (EXAS) This Quarter
www.americanbankingnews.com - June 28 at 8:42 AM
thestreet.com logoShort Interest Moves 10% Lower For EXAS
www.thestreet.com - June 27 at 10:23 PM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 27 at 7:06 PM
americanbankingnews.com logoExact Sciences Corporation (EXAS) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 24 at 1:12 PM
finance.yahoo.com logoJerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening
finance.yahoo.com - June 22 at 5:44 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Exact Sciences and Immunogen
finance.yahoo.com - June 22 at 9:53 AM
americanbankingnews.com logoVetr Inc. Downgrades Exact Sciences Corporation (EXAS) to Buy
www.americanbankingnews.com - June 20 at 12:32 AM

Social

Chart

Exact Sciences Corporation (EXAS) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff